Marc Goodman, an analyst from Leerink Partners, maintained the Buy rating on Stoke Therapeutics (STOK – Research Report). The associated price target remains the same with $18.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Marc Goodman has given his Buy rating due to a combination of factors related to Stoke Therapeutics’ promising developments and financial position. The company is progressing well with its global Phase 3 EMPEROR trial for zorevunersen, a potential breakthrough treatment for Dravet Syndrome. This trial is set to start in the second quarter of 2025, and there is significant interest from the patient community, which suggests that recruitment will likely proceed smoothly.
Furthermore, the data so far indicates that zorevunersen not only reduces seizures effectively but also improves cognition and behavior in patients, which could make it a transformative therapy. Additionally, Stoke Therapeutics is financially robust, with $380 million in cash as of the end of the first quarter of 2025, partly due to a collaboration agreement with Biogen. These factors collectively underpin Goodman’s positive outlook and Buy rating for the stock.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $35.00 price target.
Based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of STOK in relation to earlier this year.